Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO

LOS ANGELES (Reuters) - Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public this year and has begun hiring bankers, the biotechnology entrepreneur told Reuters.

FILE PHOTO - Patrick Soon-Shiong, medical researcher and chairman of the Chan Soon-Shiong Family Foundation, attends the Cancer MoonShot news conference in Taipei, Taiwan, September 26, 2016. REUTERS/Tyrone Siu

The former surgeon said in a recent interview that the new company, to be called Nant, would use most of the money raised from the initial public offering to develop a pipeline of cancer drugs, although the amount of financing has yet to be determined.

Soon-Shiong made billions by founding and selling an injectable drugmaker, followed by a company that developed a way to make a chemotherapy drug more effective.

Later, he founded Culver City, California-based NantWorks, from which he has spun off two publicly traded companies – cancer-testing company NantHealth Inc NH.O and immunotherapy developer NantKwest Inc NK.N.

Shares of both have fallen sharply and losses have mounted amid questions over whether funds from his charitable foundation have been used to drive sales. Soon-Shiong called allegations of donations being tied to sales of a cancer diagnostic test “completely untrue.”

Earlier this year, he agreed to buy the Los Angeles Times and other California newspapers for $500 million, but the deal has not yet closed.

Credit Suisse has been hired to work on the Nant IPO, and Soon-Shiong said he was in talks with two other investment banks. Credit Suisse declined comment.

Nant’s portfolio includes six compounds in clinical trials against nine tumor types. The pipeline includes versions of existing chemotherapy drugs designed to make tumors more recognizable to the immune system, methods of delivering cancer-fighting cells to tumors, and immunotherapies.

Soon-Shiong believes a multi-drug regimen could help cancer patients achieve long-term remission.

“Everybody is focusing on one little piece of the puzzle,” he said. “But the tumor is too smart. It has too many fail safes. We need to attack the entire tumor system.”

At least two of Nant's drugs are in late-stage trials: Ganitumab, an antibody licensed from Amgen Inc AMGN.O, blocks a receptor linked to cell growth and is being tested in combination with chemotherapy for advanced sarcoma patients.

Another compound, N-803, targets a protein involved in activating immune system cells and is in late-stage development for bladder cancer.


Shares of NantHealth have fallen to $3.41 from their IPO price of $14 in 2015. The company reported a first-quarter loss of around $22 million.

NantKwest trades at $3.66, down from $25 when it debuted in 2016, and reported a quarterly net loss near $27 million.

Jefferies analyst Biren Amin rates shares of NantKwest as “hold.” Citi Research has a “sell” rating on NantKwest and estimates the company has enough cash for two years of operations. Soon-Shiong said NantKwest was exploring “strategic partnerships” to fund clinical trials. He owns controlling stakes and holds the chief executive office of both companies, and will be a majority shareholder in Nant.

Health news website STAT reported last year that Soon-Shiong and his charitable foundations in 2014 gave the University of Utah $12 million for disease research, and the university later paid NantHealth $10 million for testing services.

Utah’s legislature determined that the university should have sought competitive bids for the testing, but said the donation was not tied to the purchase.

Soon-Shiong said of the Utah case: “That was a donation our foundation made to the University of Utah. They had an opportunity to go to any vendor, and they came to us.”

Reporting by Deena Beasley; Editing by Rosalba O’Brien and Peter Cooney